Corona rapid tests for hospitals. The Dortmund-based Scienion AG has developed a technology for the diagnosis of diseases. The spin-off of the Max Planck Institute for Molecular Genetics in Berlin is a system supplier and service provider for the non-contact printing of biological and chemical substances. Scienion is able to deposit DNA, antibodies, enzymes and proteins to any substrates so carefully that biological activity is not impaired.
With its specialist know-how, the 115-employee biotech company aims to help hospitals and medical practices around the world in the fight against the corona pandemic - supported by development bank for Nordrhein-Westfalen - via its NRW.BANK Venture Fund.
https://www.nrwbank.de/de/themen/eigenkapital/0822_Eigenkapital_Scienion.html
Scienion AG's dispensers are able to place smallest droplets of biological substances precisely onto various substrates.
Picture: Scienion AG
More here: https://www.scienion.com/
Learn more about how we collect, store, use and disclose your personal data when you interact with us.
This Disclaimer is defined according to the European Regulation act of General Data Protection Regulation (2016/679).
We use this data for the purposes described in our policy, which include:
Learn more here https://eapb.eu/disclaimer.html